M. T. Ergin
University of Connecticut Health Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M. T. Ergin.
International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology | 1988
Bijay Mukherji; Oskar Arnbjarnarson; Larry A. Spitznagle; Robert I. Kalish; James S. Hoffman; M. T. Ergin; Richard P. Spencer
In vivo patterns of lymphocytes sensitized against autologous tumor (in vitro) were studied in seven patients with metastatic cancer as a potential candidate for an alternative method of radioimmunodetection and adoptive immunocytotherapy. Peripheral blood lymphocytes (PBL) were either activated in Interleukin-2 (IL-2) [lymphokine activated killer (LAK) cells] or sensitized against autologous tumor cells by in vitro co-culture (IVC) and expanded in IL-2 (educated cells); both were then labelled with 111In. Labelled autologous cells (1 x 10(7)-5 x 10(8)) were administered to patients and biodistribution studied by imaging under a gamma camera at various time intervals. In 4/7 cases, imaging with the educated cells showed concentrations of radioactivity at sites that correlated positively with clinically detectable metastatic tumor. By contrast, only one instance of positive uptake was seen with the LAK cells. Other than slight fever in three cases, infusions of labelled PBL were well tolerated. Educated lymphocytes were cytotoxic against autologous tumor cells and the cytotoxic reactivities of the educated cells were maintained in continuous culture in IL-2 for 4-6 weeks. Evidence of accumulation of radiolabelled educated autologous cells at a significantly higher frequency than that of the LAK cells suggests that in vitro expanded educated PBL might be better candidates for radioimmunodetection of human cancer, and continuous cultures of such educated autologous PBL might be sources for repeated administration of these effector cells.
Clinical Immunology and Immunopathology | 1991
Nitya G. Chakraborty; Jonathan R. Sporn; Dominick R. Pasquale; M. T. Ergin; Bijay Mukherji
A functional analysis of tumor-infiltrating lymphocytes (TILs) from renal cell carcinoma (RCC) and malignant melanoma was performed. TILs were expanded in recombinant interleukin-2 (50 U/ml) in Iscoves medium. Phenotypic and functional (cytolytic vs regulatory) analyses were carried out with the fresh and expanded TIL populations after 4 weeks in culture. Only one TIL population from an RCC case (out of six cases studied) was CD8+ and demonstrated MHC class I-restricted tumor-specific cytotoxicity against the autologous RCC target. TIL populations from the other five cases became predominantly CD4+ and they neither killed the respective autologous tumor cells nor killed the NK-sensitive target K-562 cells. When studied for other functions, two CD4+ TIL populations were found to suppress the lymphokine-activated killer cell response by peripheral blood lymphocytes (PBL) in coculture. Of these two, a TIL population from an RCC case (MJ TIL) was used to study the cellular and molecular mechanisms of suppression. The MJ TIL synthesized a supernatant factor that blocked activation of resting PBL as measured by the induction of high-affinity IL-2 receptor (IL-2R) when stimulated by phytohemagglutinin but did not down-regulate the fully expressed IL-2R on activated T cells. The suppression of high-affinity IL-2R induction on T cells did not result from tumor necrosis factor-alpha and beta or from transforming growth factor-beta as these cytokines were not detected in the cell-free supernatant from the MJ TIL culture. The supernatant factor also suppressed IL-2-mediated enhancement of cytotoxicity by natural killer (NK) cells without demonstrating direct toxic effect on the NK cells. Thus, when TIL are used for adoptive immunocytotherapy, it may be useful to fully characterize them functionally, in vitro.
Proceedings of the National Academy of Sciences of the United States of America | 1995
Bijay Mukherji; Nitya G. Chakraborty; Seiji Yamasaki; Takashi Okino; Harold Yamase; Jonathan R. Sporn; S K Kurtzman; M. T. Ergin; J Ozols; J. L. Meehan
Cancer Research | 1996
Xueyou Hu; Nitya G. Chakraborty; Jonathan R. Sporn; Scott H. Kurtzman; M. T. Ergin; Bijay Mukherji
Journal of Experimental Medicine | 1989
Bijay Mukherji; Amala Guha; Nitya G. Chakraborty; Muthukumaran Sivanandham; Amgad L. Nashed; Jonathan R. Sporn; M. T. Ergin
Journal of Immunology | 1990
Nitya G. Chakraborty; D R Twardzik; Muthukumaran Sivanandham; M. T. Ergin; K E Hellstrom; Bijay Mukherji
Journal of Immunology | 1986
Bijay Mukherji; S. A. Wilhelm; Amala Guha; M. T. Ergin
Journal of Immunology | 1999
Nitya G. Chakraborty; Li Li; Jonathan R. Sporn; Scott H. Kurtzman; M. T. Ergin; Bijay Mukherji
Journal of Immunology | 1986
Bijai Mukherji; Amgad L. Nashed; Amala Guha; M. T. Ergin
The Journal of Nuclear Medicine | 1985
John J. Sziklas; John Mathews; Richard P. Spencer; Ronald J. Rosenberg; M. T. Ergin; Bruce F. Bower